Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In January last year we provided summary information about a rare form of prostate cancer known as “signet ring” cancer of the prostate (SRCP). A new report has now added to knowledge about this type of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: prognosis, ring, risk, signet | Leave a Comment »
A new study just published in the Journal of General Internal Medicine makes a strong case for the importance of individualized application of specific treatments to older men diagnosed with prostate cancer — something which you would think ought to be evident to the majority of clinicians, but apparently wasn’t
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Co-morbidity, Diagnosis, Management, mortality, prognosis, risk | Leave a Comment »
According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: NADiA, prognosis, progression, ProsVue, radical prostatectomy | Leave a Comment »
We lost count some time ago of the number of different single nucleotide polymorphism (SNPs) that had been “associated” in some way or other with risk for prostate cancer and/or with risk for more aggressive forms of prostate cancer in specific sets of people (e.g., Swedes, African-Americans, Ghanaians, Caucasians in general, you name it).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gene, prognosis, risk, single nucleotide polymorphism, SNP | 1 Comment »
No currently known biomarker can accurately predict the risk of prostate cancer recurrence at the time of or immediately following first-line treatment for localized prostate cancer. The best we can currently manage is to track a patient’s PSA level and his PSA doubling time.
Filed under: Living with Prostate Cancer, Management | Tagged: miRNA, mitochondrial, prognosis, recurrence, RNA | 3 Comments »
A new review by Epstein, currently available on line in the Journal of Urology, provides a detailed analysis of the clinical significance of various factors in determining prognostic risk for newly diagnosed and recently treated patients with localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinical, core, pathologic, prognosis, quantification, stage, T2, tumor, volume | 10 Comments »
A forthcoming paper from Tewari’s group at Weill Cornell Medical College in New York describes a new set of nomograms for assessment of risk for worsening prognosis in men with localized prostate cancer who might otherwise be considered appropriate candidates for management under active surveillance.
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, candidate, nomogram, prognosis, risk | 9 Comments »
A new paper in the Journal of Clinical Oncology provides some interesting insights into the relative merits of the two major prostate cancer risk calculators widely used today in North America: the original PCPT-based risk calculator (PRC) and the Sunnybrook risk calculator (SRC).
Filed under: Diagnosis, Risk | Tagged: biopsy, calculator, prognosis, Prostate Cancer Prevention Trial, risk, Sunnybrook | Leave a Comment »
The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) score was initially introduced in 2005 and validated in 2006 as a pre-treatment tool that could be used to assess risk for prostate cancer recurrence after first-line treatment.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CAPRA, CAPRA-S, prognosis, recurrence, risk, surgery | 5 Comments »
A research team at New York University School of Medicine has reported data suggesting that a single ultrasensitive PSA test result may be able to project risk for delayed biochemical recurrence (BCR) of prostate cancer at 3 years after a radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochgemical recurrence, prognosis, PSA, Treatment, ultrasensitive | 3 Comments »
A new study by an Austrian research team has further helped to clarify the potential prognostic significance of perineural invasion as a risk factor in the progression of localized and locally advanced forms of prostate cancer.
Filed under: Diagnosis, Management, Uncategorized | Tagged: perineural invasion, prognosis, risk | Leave a Comment »
Over the past few years we have seen a great deal of discussion of this or that new gene or single nucleotide polymorphism (SNP) or other set of genomic data and the potential of such information to improve the diagnosis or the prognosis of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, risk, Treatment | Leave a Comment »
To date there has only been one test available for assay of levels of circulating tumor cells (CTCs) in men with prostate cancer: the CellSearch test made by Veridex. This test is widely recognized to come with a variety of challenges, and the potential of CTCs in assessing risk for progression of prostate cancer (and [...]
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, circulating tumor stem cells, CTC, CTSC, outcome, prognosis | Leave a Comment »
The FierceBiomarkers e-newsletter has compiled a brief report with the above title that may be of interest to some of our readers.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, prognosis, test | Leave a Comment »
A new analysis of data from the multi-center @-Registry of patients undergoing Ablatherm-based high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer suggests that nadir levels of PSA post-treatment can be used to predict the probability of biochemical progression-free survival (bPFS) at 5 years of follow-up.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, nafir, outcome, prognosis, PSA | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site